These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 30673861)

  • 1. How to design potent and selective DYRK1B inhibitors? Molecular modeling study.
    Szamborska-Gbur A; Rutkowska E; Dreas A; Frid M; Vilenchik M; Milik M; Brzózka K; Król M
    J Mol Model; 2019 Jan; 25(2):41. PubMed ID: 30673861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel DYRK1B inhibitor AZ191 demonstrates that DYRK1B acts independently of GSK3β to phosphorylate cyclin D1 at Thr(286), not Thr(288).
    Ashford AL; Oxley D; Kettle J; Hudson K; Guichard S; Cook SJ; Lochhead PA
    Biochem J; 2014 Jan; 457(1):43-56. PubMed ID: 24134204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Theoretical Studies on the Selectivity Mechanisms of Glycogen Synthase Kinase 3β (GSK3β) with Pyrazine ATP-competitive Inhibitors by 3DQSAR, Molecular Docking, Molecular Dynamics Simulation and Free Energy Calculations.
    Zhu J; Wu Y; Xu L; Jin J
    Curr Comput Aided Drug Des; 2020; 16(1):17-30. PubMed ID: 31284868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of two potential glycogen synthase kinase 3β inhibitors for the treatment of osteosarcoma.
    Lu K; Wang X; Chen Y; Liang D; Luo H; Long L; Hu Z; Bao J
    Acta Biochim Biophys Sin (Shanghai); 2018 May; 50(5):456-464. PubMed ID: 29546355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyrido[2,3-d]pyrimidines: discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors.
    Anderson K; Chen Y; Chen Z; Dominique R; Glenn K; He Y; Janson C; Luk KC; Lukacs C; Polonskaia A; Qiao Q; Railkar A; Rossman P; Sun H; Xiang Q; Vilenchik M; Wovkulich P; Zhang X
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6610-5. PubMed ID: 24239188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A wake-up call to quiescent cancer cells - potential use of DYRK1B inhibitors in cancer therapy.
    Becker W
    FEBS J; 2018 Apr; 285(7):1203-1211. PubMed ID: 29193696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel and Potential Small Molecule Scaffolds as DYRK1A Inhibitors by Integrated Molecular Docking-Based Virtual Screening and Dynamics Simulation Study.
    Shahroz MM; Sharma HK; Altamimi ASA; Alamri MA; Ali A; Ali A; Alqahtani S; Altharawi A; Alabbas AB; Alossaimi MA; Riadi Y; Firoz A; Afzal O
    Molecules; 2022 Feb; 27(4):. PubMed ID: 35208955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and optimization of a novel series of Dyrk1B kinase inhibitors to explore a MEK resistance hypothesis.
    Kettle JG; Ballard P; Bardelle C; Cockerill M; Colclough N; Critchlow SE; Debreczeni J; Fairley G; Fillery S; Graham MA; Goodwin L; Guichard S; Hudson K; Ward RA; Whittaker D
    J Med Chem; 2015 Mar; 58(6):2834-44. PubMed ID: 25738750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 10-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acids are selective inhibitors of DYRK1A.
    Falke H; Chaikuad A; Becker A; Loaëc N; Lozach O; Abu Jhaisha S; Becker W; Jones PG; Preu L; Baumann K; Knapp S; Meijer L; Kunick C
    J Med Chem; 2015 Apr; 58(7):3131-43. PubMed ID: 25730262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unravelling the Selectivity of 6,7-Dimethyl Quinoxaline Analogs for Kinase Inhibition: An Insight towards the Development of Alzheimer's Therapeutics.
    Kumar Jain A; Gupta A; Karthikeyan C; Trivedi P; Dutt Konar A
    Chem Biodivers; 2021 Nov; 18(11):e2100364. PubMed ID: 34486216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of dual kinase inhibitors of CK2 and GSK3β: combined qualitative and quantitative pharmacophore modeling approach.
    Pardhi T; Vasu K
    J Biomol Struct Dyn; 2018 Jan; 36(1):177-194. PubMed ID: 27960601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of a potent inhibitor of class 1 DYRK kinases as a suppressor of adipogenesis.
    Masaki S; Kii I; Sumida Y; Kato-Sumida T; Ogawa Y; Ito N; Nakamura M; Sonamoto R; Kataoka N; Hosoya T; Hagiwara M
    Bioorg Med Chem; 2015 Aug; 23(15):4434-4441. PubMed ID: 26145823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of novel amide-derivatized 2,4-bispyridyl thiophenes as highly potent and selective Dyrk1A inhibitors. Part II: Identification of the cyclopropylamide moiety as a key modification.
    Darwish SS; Abdel-Halim M; ElHady AK; Salah M; Abadi AH; Becker W; Engel M
    Eur J Med Chem; 2018 Oct; 158():270-285. PubMed ID: 30223116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Theoretical studies on the selective mechanisms of GSK3β and CDK2 by molecular dynamics simulations and free energy calculations.
    Zhao S; Zhu J; Xu L; Jin J
    Chem Biol Drug Des; 2017 Jun; 89(6):846-855. PubMed ID: 27863047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multi-step virtual screening to develop selective DYRK1A inhibitors.
    Koyama T; Yamaotsu N; Nakagome I; Ozawa SI; Yoshida T; Hayakawa D; Hirono S
    J Mol Graph Model; 2017 Mar; 72():229-239. PubMed ID: 28129593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploiting the repertoire of CK2 inhibitors to target DYRK and PIM kinases.
    Cozza G; Sarno S; Ruzzene M; Girardi C; Orzeszko A; Kazimierczuk Z; Zagotto G; Bonaiuto E; Di Paolo ML; Pinna LA
    Biochim Biophys Acta; 2013 Jul; 1834(7):1402-9. PubMed ID: 23360763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Simulation Studies on the Binding Selectivity of Type-I Inhibitors in the Complexes with ROS1 versus ALK.
    Tian Y; Yu Y; Shen Y; Wan H; Chang S; Zhang T; Wan S; Zhang J
    J Chem Inf Model; 2017 Apr; 57(4):977-987. PubMed ID: 28318251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and Functional Characterization of a Potent, Selective, and Metabolically Stable PROTAC of the Protein Kinases DYRK1A and DYRK1B.
    Wilms G; Schofield K; Maddern S; Foley C; Shaw Y; Smith B; Basantes LE; Schwandt K; Babendreyer A; Chavez T; McKee N; Gokhale V; Kallabis S; Meissner F; Rokey SN; Dunckley T; Montfort WR; Becker W; Hulme C
    J Med Chem; 2024 Oct; 67(19):17259-17289. PubMed ID: 39344427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uncovering Molecular Bases Underlying Bone Morphogenetic Protein Receptor Inhibitor Selectivity.
    Alsamarah A; LaCuran AE; Oelschlaeger P; Hao J; Luo Y
    PLoS One; 2015; 10(7):e0132221. PubMed ID: 26133550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian cancer cells, not normal cells, are damaged by Mirk/Dyrk1B kinase inhibition.
    Hu J; Deng H; Friedman EA
    Int J Cancer; 2013 May; 132(10):2258-69. PubMed ID: 23114871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.